<qa>  Prior treatment with EGFR targeting therapies or treatment with EGFR- or HER212. Prior treatment with EGFR targeting therapies or treatment with EGFR- or HER2 inhibiting drugs within the past four weeks before start of therapy or concomitantly with this trial. 